| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/06/2005 | EP1520859A2 Hydrophilic signal oligopeptides and methods of therapeutic use |
| 04/06/2005 | EP1520589A1 Erythropoietin in the treatment of domestic and livestock animals for anaemia |
| 04/06/2005 | EP1520586A1 Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases |
| 04/06/2005 | EP1520582A2 Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
| 04/06/2005 | EP1520050A2 Tr4/tr2 response elements |
| 04/06/2005 | EP1520042A2 Chromosome 3, 5 and 11 genes involved in premature canities |
| 04/06/2005 | EP1520032A2 Lung cancer therapeutics and diagnostics |
| 04/06/2005 | EP1520026A1 Nucleic acid sequence coding for enzyme delta-12-desaturase and originating from fragilariopsis cylindrus, associated polypeptide, and use of this nucleic acid sequence and polypeptide |
| 04/06/2005 | EP1520023A2 Human nuclear hormone receptor |
| 04/06/2005 | EP1520022A2 Rna-interference by single-stranded rna molecules |
| 04/06/2005 | EP1520021A2 Antisense modulation of lrh1 expression |
| 04/06/2005 | EP1520018A1 Process for producing a virus-inactivated thrombin preparation |
| 04/06/2005 | EP1520015A2 Plant deoxyribonucleoside kinase enzymes and their use |
| 04/06/2005 | EP1519957A2 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 04/06/2005 | EP1519955A2 Nuclear hormone receptor |
| 04/06/2005 | EP1519953A1 Avian cytokines, such il-12, comprising a p40 and/or p35 subunit(s) |
| 04/06/2005 | EP1519951A2 Cationic linear peptides having antibacterial and/or antifungal properties |
| 04/06/2005 | EP1519950A2 Components of the presenilin-complex |
| 04/06/2005 | EP1519946A2 Novel variants of the papm polypeptide of bacteria of genus streptomyces |
| 04/06/2005 | EP1519945A2 Novel chemokine binding peptides capable of modulating the biological activity of chemokines |
| 04/06/2005 | EP1519944A1 Processes for the preparation of fibrinogen |
| 04/06/2005 | EP1519942A2 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 04/06/2005 | EP1519751A2 Compositions comprising panthetine for the treatment of dyslipidemia |
| 04/06/2005 | EP1519750A2 Oxygenating agents for enhancing host responses to microbial infections |
| 04/06/2005 | EP1519749A1 Chemotactic factor inhibitor for modulating inflammatory reactions |
| 04/06/2005 | EP1519744A2 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
| 04/06/2005 | EP1519743A1 Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| 04/06/2005 | EP1519742A2 Osteoclast-associated receptor |
| 04/06/2005 | EP1519737A2 Fibrin nanoparticles and uses thereof |
| 04/06/2005 | EP1519736A2 Use of hec1 antagonists in the treatment of proliferative disorders and cancer |
| 04/06/2005 | EP1519732A1 Use of vasopeptidase inhibitors in the treatment of nephropathy |
| 04/06/2005 | EP1519725A2 Methods for targeting quadruplex dna |
| 04/06/2005 | EP1519717A1 Controlled release composition |
| 04/06/2005 | EP1360282B1 Method for inactivation of TSE |
| 04/06/2005 | EP1284997B1 Therapeutic compounds for ovarian cancer |
| 04/06/2005 | EP1278761B1 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 04/06/2005 | EP1276754A4 Materials and methods relating to lipid metabolism |
| 04/06/2005 | EP1237936B1 Molecularly imprinted polymers produced by template polymerisation |
| 04/06/2005 | EP1224469B1 Method of screening for inhibitors of asp2 |
| 04/06/2005 | EP1218494B1 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 04/06/2005 | EP1212100B1 Delivery system for antidandruff agent |
| 04/06/2005 | EP1162993B1 Use of casb616 polypeptides and polynucleotides for cancer treatment |
| 04/06/2005 | EP1117769B1 Cloning and recombinant production of polistinae venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon |
| 04/06/2005 | EP1113809B1 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor |
| 04/06/2005 | EP1100529B1 Thymosin beta 4 promotes wound repair |
| 04/06/2005 | EP1097234B1 Method for improving the gene transfer of genetic material in mammalian cells through the use of p21 (waf-1) |
| 04/06/2005 | EP1040190B1 Serine proteinase inhibitors |
| 04/06/2005 | EP1002093B1 Preparation and use of recombinant influenza a virus m2 constructs and vaccines |
| 04/06/2005 | EP0847757B1 Medicine comprising hgf gene |
| 04/06/2005 | EP0827407B1 Peptides of the tsp-1 receptor cd36 for the treatment of diseases caused by a dysregulation of tgf-beta1 |
| 04/06/2005 | EP0748219B1 Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| 04/06/2005 | CN1604968A Methods to treat diabetes and related conditions based on polymorphisms in the TCF-1 gene |
| 04/06/2005 | CN1604965A 生长激素融合蛋白 Growth hormone fusion protein |
| 04/06/2005 | CN1604963A Method for the in vitro synthesis of short double stranded RNAs |
| 04/06/2005 | CN1604911A Repressors for HIV transcription and methods thereof |
| 04/06/2005 | CN1604910A Affinity enhancement agents |
| 04/06/2005 | CN1604909A Cyclic peptides as g-protein-coupled receptor antagonists |
| 04/06/2005 | CN1604908A Process for the preparation of echinocandin derivatives |
| 04/06/2005 | CN1604906A Antisense antiviral agent and method for treating ssRNA viral infection |
| 04/06/2005 | CN1604795A Combination motif immune stimulatory oligonucleotides with improved activity |
| 04/06/2005 | CN1604790A Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
| 04/06/2005 | CN1604789A Thymosin augmentation of genetic immunization |
| 04/06/2005 | CN1604788A High-concentration protein formulations and method of manufacture |
| 04/06/2005 | CN1604787A Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI) |
| 04/06/2005 | CN1604783A Drug for treating a fibrotic disease through rna interfence |
| 04/06/2005 | CN1603405A Preparation method for high purity lumbrukinase and pharmaceutical preparation made therefrom |
| 04/06/2005 | CN1603346A Protein, products containing same, and their use in diagnosis, treatment and /or prevention of SARS related disease |
| 04/06/2005 | CN1603342A Caspase-8 interacting proteins |
| 04/06/2005 | CN1603341A Human calcium ion / calmodulin deopendent protein kinase II inhibitory protein alpha, its coded sequence and use |
| 04/06/2005 | CN1603340A Antitumor activity of squash protein and use thereof |
| 04/06/2005 | CN1603338A Selenium-containing polypeptide and its use in medicine, food etc |
| 04/06/2005 | CN1602955A Biological bacteria inhibitor |
| 04/06/2005 | CN1602954A Pharmaceutical composition with liver cell protecting function |
| 04/06/2005 | CN1602953A Thrombogenesis inhibiting medicine |
| 04/06/2005 | CN1602952A Tumor cell apoptosis accelerating medicine |
| 04/06/2005 | CN1602951A Nasally administered formulation of osteogenic growth peptide |
| 04/06/2005 | CN1602841A Immuno-modulatory agents administration form for whole body or local immunity disorder |
| 04/06/2005 | CN1195860C Delivery of biologically active polypeptides |
| 04/06/2005 | CN1195859C Modified human granulocyte-colony stimulating factor and process for producing same |
| 04/06/2005 | CN1195858C OB fusion protein compositions and methods |
| 04/06/2005 | CN1195853C Neurotrophic factor NNT-1 |
| 04/06/2005 | CN1195852C Biotin-binding receptor molecules |
| 04/06/2005 | CN1195851C Compounds for immunotherapy of prostate cancer and their use |
| 04/06/2005 | CN1195849C APPIL-a novel protein with growth effects |
| 04/06/2005 | CN1195845C Human source aprotinin gene, protein of said gene code and its application |
| 04/06/2005 | CN1195788C Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 04/06/2005 | CN1195778C Cell adhension inhibitors |
| 04/06/2005 | CN1195777C Novel insulin derivatives having rapid onset of action |
| 04/06/2005 | CN1195776C Treatmet of obesity |
| 04/06/2005 | CN1195775C Glucoprotein having inhibitory activity to pyroric spirillar colonization |
| 04/06/2005 | CN1195774C HEV antigenic peptide and its method |
| 04/06/2005 | CN1195773C Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 04/06/2005 | CN1195767C Antithrombotic compound |
| 04/06/2005 | CN1195755C Pyrrolo [2, 3-d] pyrimidine compounds |
| 04/06/2005 | CN1195551C Novel agent for controlling cell activity |
| 04/06/2005 | CN1195546C Application of monoclone antibody combined with CD154 for inhibiting rejection of insulin generating transplanted tissue |
| 04/06/2005 | CN1195544C Liver function ameliorating agents for chronic hepatitis |
| 04/06/2005 | CN1195543C Method for administering monomeric insulin analogs |
| 04/06/2005 | CN1195526C Medicinal products containing antimer pure beta-D-dioxypentacyclic nucleoside |
| 04/06/2005 | CN1195512C Use of fatty materials for prevention or reduction of microorganism adherence on skin and/or mucous membrane |